ACIP Meetings
Next meeting scheduled for February 23-24, 2022

MMWR News Synopsis Friday, January 14, 2022
Selected Content
:: Supplement: Standards Required for the Development of CDC Evidence-Based Guidelines
:: Impact of the DREAMS Program on New HIV Diagnoses in Adolescent Girls and Young Women Attending Antenatal Care — Lesotho, 2015–2020
:: Previously Released: Effectiveness of BNT162b2 (Pfizer-BioNTech) mRNA Vaccination Against Multisystem Inflammatory Syndrome in Children Among Persons Aged 12–18 Years — United States, July–December 2021
:: Previously Released: Risk for Newly Diagnosed Diabetes >30 Days After SARS-CoV-2 Infection Among Persons Aged <18 years — United States, March 1, 2020–June 28, 2021

Coronavirus Disease 2019 (COVID-19)– CDC
Approximately 25 announcements/reports/data summaries.

Africa CDC [to 15 Jan 2022]
http://www.africacdc.org/
News
No new digest content identified.

China CDC http://www.chinacdc.cn/en/

National Health Commission of the People’s Republic of China [to 15 Jan 2022]
http://en.nhc.gov.cn/
News
Nearly 2.92b COVID-19 vaccine doses administered on Chinese mainland
2022-01-14
Nearly 2.92 billion COVID-19 vaccine doses had been administered on the Chinese mainland as of Wednesday, data from the National Health Commission showed on Jan 13.

Nation plans to launch free HPV vaccinations
2022-01-14
China will gradually launch free human papillomavirus vaccinations nationwide to protect women and girls from cervical cancer, starting in pilot regions, the National Health Commission said.

National Medical Products Administration – PRC [to 15 Jan 2022]
http://english.nmpa.gov.cn/
News
Nearly 2.92b COVID-19 vaccine doses administered on Chinese mainland
2022-01-14
Nearly 2.92 billion COVID-19 vaccine doses had been administered on the Chinese mainland as of Wednesday, data from the National Health Commission showed on Jan 13.

CCDC Weekly Reports: Current Volume (4)
2022-01-14 / No. 2
View  PDF of this issue
:: Perspectives: Public Health Control Measures for the Co-circulation of Influenza and SARS-CoV-2 During Influenza Seasons
:: Notes from the Field: Cholera Caused by a New Clone of Serogroup O1 Vibrio cholerae — Beijing Municipality, China, June 2021
:: Notifiable Infectious Diseases Reports: Reported Cases and Deaths of National Notifiable Infectious Diseases — China, November, 2021

::::::

Organization Announcements
Editor’s Note:
Careful readers will note that the number and range of organizations now monitored in our Announcements section below has grown as the impacts of the pandemic have spread across global economies, supply chains and programmatic activity of multilateral agencies and INGOs.

Airfinity
https://www.airfinity.com/insights
INSIGHTS & COMPANY NEWS
240 million COVID-19 vaccines set to expire by March, according to analysis by Airfinity
Jan 12, 2022
Airfinity estimates 241 million COVID-19 vaccine doses purchased by the G7 and EU will go unused and expire by March this year.
In September 2021, Airfinity forecast 100 million vaccines would expire by the end of 2021. Today UNICEF said poorer nations rejected more than 100 million doses in December alone due to a short shelf life. 
Airfinity’s forecast is based on analysis of G7 and EU vaccine supply while accounting for doses administered, boosters for everyone over 12 years-old, vaccine hesitancy and donations.
Co-founder and CEO of Airfinity, Rasmus Bech Hansen says, “These numbers show that vaccinating the world is now largely a distribution problem and no longer a supply issue. Even after successful booster rollouts, there are surplus doses available that risk going to waste if not shared very soon. The emergence of Omicron and the likelihood of future variants shows there is no time to waste.”
Dr Matt Linley, Lead Analyst at Airfinity, says, “Countries need these vaccines to have a minimum shelf life of two months, otherwise there isn’t enough time to get them to the people who need them. Once this two month requirement is factored into our analysis the number of potentially wasted doses could rise to 500 million by March.”

Paul G. Allen Frontiers Group [to 15 Jan 2022]
https://alleninstitute.org/news-press/
News
No new digest content identified.

BARDA – U.S. Department of HHS [to 15 Jan 2022]
https://www.phe.gov/about/barda/Pages/default.aspx
News
HHS Secretary Becerra renews COVID-19 pandemic public health emergency declaration, marking two years of global pandemic response
Friday, January 14, 2022

DOD, HHS Purchase COVID-19 Antigen Over-the-Counter Test Kits in Support of POTUS’ 500 Million Free At-Home COVID-19 Tests
Thursday, January 13, 2022

BMGF – Gates Foundation [to 15 Jan 2022]
https://www.gatesfoundation.org/ideas/media-center
Press Releases and Statements
No new digest content identified.

Bill & Melinda Gates Medical Research Institute [to 15 Jan 2022]
https://www.gatesmri.org/
The Bill & Melinda Gates Medical Research Institute is a non-profit biotech organization. Our mission is to develop products to fight malaria, tuberculosis, and diarrheal diseases—three major causes of mortality, poverty, and inequality in developing countries. The world has unprecedented scientific tools at its disposal; now is the time to use them to save the lives of the world’s poorest people
No new digest content identified.

CARB-X [to 15 Jan 2022]
https://carb-x.org/
News
No new digest content identified.

Center for Vaccine Ethics and Policy – GE2P2 Global Foundation [to 15 Jan 2022]
https://centerforvaccineethicsandpolicy.net/
News/Analysis/Statements
:: Past weekly editions and posting of all segments of Vaccines and Global Health: The Week in Review are available here.
:: Informed Consent: A Monthly Review – January 2022 is now posted here

CEPI – Coalition for Epidemic Preparedness Innovations [to 15 Jan 2022]
http://cepi.net/
Latest News
No new digest content identified.

DARPA – Defense Advanced Research Projects Agency [U.S.] [to 15 Jan 2022
https://www.darpa.mil/news
News
No new digest content identified.

Duke Global Health Innovation Center [to 15 Jan 2022]
https://dukeghic.org/
Our Blog
No new digest content identified.

EDCTP [to 15 Jan 2022]
http://www.edctp.org/
The European & Developing Countries Clinical Trials Partnership (EDCTP) aims to accelerate the development of new or improved drugs, vaccines, microbicides and diagnostics against HIV/AIDS, tuberculosis and malaria as well as other poverty-related and neglected infectious diseases in sub-Saharan Africa, with a focus on phase II and III clinical trials
News
No new digest content identified.

Emory Vaccine Center [to 15 Jan 2022]
http://www.vaccines.emory.edu/
Vaccine Center News
No new digest content identified.

European Vaccine Initiative [to 15 Jan 2022]
http://www.euvaccine.eu/
Latest News, Events
No new digest content identified.

Fondation Merieux [to 15 Jan 2022]
http://www.fondation-merieux.org/
News, Events
No new digest content identified.

Gavi [to 15 Jan 2022]
https://www.gavi.org/
News Releases
No new digest content identified.

GHIT Fund [to 15 Jan 2022]
https://www.ghitfund.org/newsroom/press
January 11, 2022
GHIT Fund Announces Appointment of Dr. Osamu Kunii as New CEO
The Global Health Innovative Technology Fund (GHIT) today announced the appointment of Dr. Osamu Kunii as the organization’s new CEO, effective March 1st, 2022. Dr. Osamu Kunii is currently serving as a Management Executive Committee member of the Global Fund to Fight AIDS, Tuberculosis and Malaria, as Head of the Strategy, Investment and Impact Division…

Global Fund [to 15 Jan 2022]
https://www.theglobalfund.org/en/news/
News & Stories
No new digest content identified.

Global Research Collaboration for Infectious Disease Preparedness [GloPID-R] [to 15 Jan 2022]
https://www.glopid-r.org/news/
News
No new digest content identified.

Hilleman Laboratories [to 15 Jan 2022]
http://www.hillemanlabs.org/
News & Insights
No new digest content identified.

HHMI – Howard Hughes Medical Institute [to 15 Jan 2022]
https://www.hhmi.org/news
Press Room
No new digest content identified.

Human Vaccines Project [to 15 Jan 2022]
http://www.humanvaccinesproject.org/
News
HVP COVID Report
Jan 13, 2022
Eric Topol: “We got Lucky with Omicron”

IAVI [to 15 Jan 2022]
https://www.iavi.org/newsroom
Latest News
No new digest content identified.

International Coalition of Medicines Regulatory Authorities [ICMRA]
http://www.icmra.info/drupal/en/news
Selected Statements, Press Releases, Research
No new digest content identified.

ICRC [to 15 Jan 2022]
https://www.icrc.org/en/whats-new
Selected News Releases, Statements, Reports
Ukraine: Ongoing, active conflict a cause of a heavy humanitarian toll
A statement from Dominik Stillhart, the director of operations for the ICRC
12-01-2022 | Statement

IFFIm
http://www.iffim.org/
Press Releases/Announcements
No new digest content identified.

IFRC [to 15 Jan 2022]
http://media.ifrc.org/ifrc/news/press-releases/
Selected Press Releases, Announcements
South Asia: Omicron threatens to overwhelm health systems
12/01/2022 | Press release
Kuala Lumpur/Delhi, 12 January 2022: The Omicron variant is fuelling a rapid surge of COVID-19 across South Asia that threatens to overwhelm health systems still reeling from a deadly wave of the Delta variant last year.
Countries across South Asia from India to Nepal and Bangladesh are reporting alarming increases in COVID-19 infections, with India alone reporting a 2,013 per cent increase in COVID-19 infections in the past month, with cases now topping 179,000 in a day.
The new wave is causing further misery for hundreds of millions of people across South Asia, already living in extreme poverty, exacerbated by COVID-19 over the past two years.
Udaya Regmi, International Federation of Red Cross and Red Crescent Societies (IFRC) Head of Delegation, South Asia, said: “This latest surge of COVID-19 spells immense danger for millions of people and health systems across South Asia. Omicron is spreading fast and while vaccination rates have been soaring, after such tragic loss of life last year, fear is mounting of record infection rates.
“People everywhere want this pandemic to end but we must boost efforts to keep people safe with the basics, by wearing masks, avoiding crowds, and getting fully vaccinated where possible.”…

Institut Pasteur [to 15 Jan 2022]
https://www.pasteur.fr/en/press-area
Press Documents
Press release 11.01.2022
Identification of a novel therapeutic target in Multiple Myeloma
Multiple myeloma is a cancer of the bone marrow, with a life expectancy of less than 5 years post-diagnosis. Proteasome…

IOM / International Organization for Migration [to 15 Jan 2022]
http://www.iom.int/press-room/press-releases
News – Selected
No new digest content identified.

ISC / International Science Council [to 15 Jan 2022]
https://council.science/current/
ISC is a non-governmental organization with a unique global membership that brings together 40 international scientific Unions and Associations and over 140 national and regional scientific organizations including Academies and Research Councils.
News
No new digest content identified.

IVAC [to 15 Jan 2022]
https://www.jhsph.edu/research/centers-and-institutes/ivac/index.html
Updates; Events
No new digest content identified.

IVI [to 15 Jan 2022]
http://www.ivi.int/
IVI News & Announcements
No new digest content identified.

Johns Hopkins Center for Health Security [to 15 Jan 2022]
https://www.centerforhealthsecurity.org/news/center-news/
Center News
Experts Encourage School Administrators to Reduce COVID-19 Transmission by Improving Indoor Air in Schools
January 11, 2022

MSF/Médecins Sans Frontières [to 15 Jan 2022]
http://www.msf.org/
Latest [Selected Announcements]
No new digest content identified.

National Academy of Medicine – USA [to 15 Jan 2022]
https://nam.edu/programs/
Selected News/Programs/Events
No new digest content identified.

National Academy of Sciences – USA [to 15 Jan 2022]
http://www.nasonline.org/news-and-multimedia/
News
No new digest content identified.

National Vaccine Program Office – U.S. HHS [to 15 Jan 2022]
https://www.hhs.gov/vaccines/about/index.html
Upcoming Meetings/Latest Updates
National Vaccine Advisory Committee [NVAC] 2022 Meetings
February 10-11, 2022

NIH [to 15 Jan 2022]
http://www.nih.gov/news-events/news-releases
News Releases
No new digest content identified.

OECD [to 15 Jan 2022]
http://www.oecd.org/newsroom/publicationsdocuments/bydate/
Newsroom
No new digest content identified.

PATH [to 15 Jan 2022]
https://www.path.org/media-center/
Press Releases
No new digest content identified.

Sabin Vaccine Institute [to 15 Jan 2022]
http://www.sabin.org/updates/pressreleases
Statements and Press Releases
No new digest content identified.

UNAIDS [to 15 Jan 2022]
http://www.unaids.org/en
Selected Press Releases/Reports/Statements
No new digest content identified.

UNHCR Office of the United Nations High Commissioner for Refugees [to 15 Jan 2022]
http://www.unhcr.org/en-us/media-centre.htmlS
Selected News Releases, Announcements
No new digest content identified.

UNICEF [to 15 Jan 2022]
https://www.unicef.org/media/press-releases
Press Releases, News Notes, Statements [Selected]
No new digest content identified.

Unitaid [to 15 Jan 2022]
https://unitaid.org/
Featured News
2 January 2022
FIND and Unitaid, through the ACT-Accelerator, seek organizations to advocate and raise awareness on COVID-19 testing and treatment solutions
FIND and Unitaid today launched a request for proposals (RFP) to select services of organizations, with a proven record of advocacy and awareness-raising in healthcare in low- and middle-income countries, to implement projects to achieve the below specific objectives:
Increase access and uptake to COVID-19 testing and therapeutics, as they get recommended, through development and implementation of robust and evidence-based advocacy strategies supported by advocacy, literacy and communication materials and initiatives adapted to specific population groups, regional and country contexts
Disseminate and amplify these materials and initiatives through appropriate communication channels to increase prioritization of COVID-19 testing and linkage to treatment in the national pandemic response as well as generate demand for testing and therapeutics within relevant target groups
…The total budget envelope for this RFP is anticipated to be US$ ~2 million. This amount will be distributed among selected partners with an average award of no less than US$50,000 to a maximum of US$100,000. Proposals along with appendices/supporting documents must be received by FIND at [advocacy_RFP@finddx.org] no later than 2 February 2022 at 17h00 CET. Two applicant webinars are being organized to provide an overview of the RFP and answer queries. These webinars will take place on 19 January and 20 January.

USAID [to 15 Jan 2022]
https://www.usaid.gov/news-information/press-releases/2021
Selected Press Releases, Statements, Announcements
No new digest content identified.

Vaccine Equity Cooperative [nee Initiative] [to 15 Jan 2022]
https://vaccineequitycooperative.org/news/
News
No new digest content identified.

Vaccination Acceptance & Demand Initiative [Sabin) [to 15 Jan 2022]
https://www.vaccineacceptance.org/
Announcements
No new digest content identified.

Vaccine Confidence Project [to 15 Jan 2022]
http://www.vaccineconfidence.org/
News, Research and Reports
No new digest content identified.

Vaccine Education Center – Children’s Hospital of Philadelphia [to 15 Jan 2022]
http://www.chop.edu/centers-programs/vaccine-education-center
News
No new digest content identified.

Wellcome Trust [to 15 Jan 2022]
https://wellcome.ac.uk/news
News. Opinion, Reports
News
Wellcome’s new strategy gets extra boost, as organisation makes strongest returns in over two decades
10 January 2022
Wellcome is making its biggest funding commitment to science and health in our 85-year history, thanks to our strongest investment returns in 25 years.
[See Perspective above for detail]

The Wistar Institute [to 15 Jan 2022]
https://www.wistar.org/news/press-releases
Press Releases
No new digest content identified.

WFPHA: World Federation of Public Health Associations [to 15 Jan 2022]
https://www.wfpha.org/
Latest News – Blog
No new digest content identified.

World Bank [to 15 Jan 2022]
http://www.worldbank.org/en/news/all
Selected News, Announcements
Global Growth to Slow through 2023, Adding to Risk of ‘Hard Landing’ in Developing Economies
Spread of COVID-19 Variants Alongside Inflation, Debt, and Inequality Intensifies Uncertainty WASHINGTON, Jan. 11, 2022—Following a strong rebound in 2021, the global economy is entering a pronounced slowdown…
Date: January 11, 2022 Type: Press Release
[See Perspectives above for detail]

World Bank Statement at the 8th Facilitation Council Meeting of the Access to COVID-19 Tolls Accelerator (ACT-A)
Let me reiterate the World Bank Group’s support for ACT-A’s objectives. We continue to be an engaged partner of ACT-A and we support its shared objective of expanding equitable and affordable access to…
Date: January 10, 2022 Type: Speeches and Transcripts
[See Perspectives above for detail]

World Organisation for Animal Health (OIE) [to 15 Jan 2022]
https://www.oie.int/en/media/news/
Press Releases, Statements
No new digest content identified.

WTO – World Trade Organisation [to 15 Jan 2022]
http://www.wto.org/english/news_e/news_e.htm
WTO News and Events
General Council discusses India’s call for virtual ministerial meeting on pandemic response
10 January 2022
[See Perspective above for detail]

::::::

ARM [Alliance for Regenerative Medicine] [to 15 Jan 2022]
https://alliancerm.org/press-releases/
Selected Press Releases
No new digest content identified.

BIO [to 15 Jan 2022]
https://www.bio.org/press-releases
Press Releases, Letters, Testimony, Comments [Selected]
No new digest content identified.

DCVMN – Developing Country Vaccine Manufacturers Network [to 15 Jan 2022]
http://www.dcvmn.org/
News; Upcoming events
No new digest content identified.

ICBA – International Council of Biotechnology Associations [to 15 Jan 2022]
https://internationalbiotech.org/news/
News
No new digest content identified.

IFPMA [to 15 Jan 2022]
http://www.ifpma.org/resources/news-releases/
Selected Press Releases, Statements, Publications
No new digest content identified.

International Generic and Biosimilar Medicines Association [IGBA]
https://www.igbamedicines.org/
News
Vivian Frittelli takes over the position of IGBA Chair
Geneva, 12 January 2022
IGBA, the International Generic and Biosimilar Medicines Association (IGBA), representing global
manufacturers of generic and biosimilar medicines, announced today that Vivian Frittelli, Chief Executive of Generic and Biosimilar Medicines of Southern Africa (GBM), is taking over the position of IGBA Chair for 2022 from Sudarshan Jain, Secretary General of the Indian Pharmaceutical Alliance (IPA)…

International Alliance of Patients’ Organizations – IAPO [to 15 Jan 2022]
https://www.iapo.org.uk/news/topic/6
Press and media [Selected]
No new digest content identified.

PhRMA [to 15 Jan 2022]
http://www.phrma.org/
Latest News [Selected]
No new digest content identified.

Journal Watch
Vaccines and Global Health: The Week in Review continues its weekly scanning of key peer-reviewed journals to identify and cite articles, commentary and editorials, books reviews and other content supporting our focu-s on vaccine ethics and policy. Journal Watch is not intended to be exhaustive, but indicative of themes and issues the Center is actively tracking. We selectively provide full text of some editorial and comment articles that are specifically relevant to our work. Successful access to some of the links provided may require subscription or other access arrangement unique to the publisher.
If you would like to suggest other journal titles to include in this service, please contact David Curry at: david.r.curry@centerforvaccineethicsandpolicy.org

AMA Journal of Ethics
Volume 24, Number 1: E1-105 Jan 2022
https://journalofethics.ama-assn.org/issue/inequity-along-medicaldental-divide

Inequity Along the Medical/Dental Divide
Dental and medical health systems in the United States have evolved as fully separate entities. This division exacerbates health inequity, since patients’ poor oral health affects their general health. The professionally entrenched view that what’s in patients’ mouths is somehow isolated from what’s going on in the rest of their bodies is one all clinicians need to resist, since this view can be a source of harm, particularly among vulnerable patients and communities. Practical and ethical strategies for better aligning medical and dental goals of care are considered in this issue.

Artificial Intelligence – An International Journal
Volume 302 January 2022
https://www.sciencedirect.com/journal/artificial-intelligence/vol/302/suppl/C

BMC Cost Effectiveness and Resource Allocation
http://resource-allocation.biomedcentral.com/
(Accessed 15 Jan 2022)
Optimal strategies to screen health care workers for COVID-19 in the US: a cost-effectiveness analysis
Authors: Sigal Maya, Guntas Padda, Victoria Close, Trevor Wilson, Fareeda Ahmed, Elliot Marseille and James G. Kahn
Content type: Research
15 January 2022

BMC Pregnancy and Childbirth
http://www.biomedcentral.com/bmcpregnancychildbirth/content
(Accessed 15 Jan 2022)

Women’s views on accepting COVID-19 vaccination during and after pregnancy, and for their babies: a multi-methods study in the UK
COVID-19 vaccines are advised for pregnant women in the United Kingdom (UK) however COVID-19 vaccine uptake among pregnant women is inadequate.
Authors: Helen Skirrow, Sara Barnett, Sadie Bell, Lucia Riaposova, Sandra Mounier-Jack, Beate Kampmann and Beth Holder
Citation: BMC Pregnancy and Childbirth 2022 22:33
Content type: Research
Published on: 14 January 2022

BMC Public Health
http://bmcpublichealth.biomedcentral.com/articles
(Accessed 15 Jan 2022)

Vaccination against tuberculosis, polio and hepatitis B at birth in Podor health district, Northern Senegal: cross-sectional study of vaccination coverage and its associated factors
In Senegal, studies focusing specifically on vaccination coverage with the Bacille de Calmette et Guérin (BCG) vaccine, the birth dose of oral polio vaccine (OPV zero dose) and the birth dose of hepatitis B (H…
Authors: Oumar Bassoum, Ndeye Mareme Sougou, Mouhamadou Faly Ba, Malick Anne, Mamoudou Bocoum, Alioune Dieye, Cheikh Sokhna and Anta Tal-Dia
Citation: BMC Public Health 2022 22:110
Content type: Research
Published on: 15 January 2022

BMC Public Health
http://bmcpublichealth.biomedcentral.com/articles
(Accessed 15 Jan 2022)

COVID-19 vaccine hesitancy in the UK: a longitudinal household cross-sectional study
The approved COVID-19 vaccines have shown great promise in reducing disease transmission and severity of outcomes. However, the success of the COVID-19 vaccine rollout is dependent on public acceptance and wil…
Authors: Kausik Chaudhuri, Anindita Chakrabarti, Joht Singh Chandan and Siddhartha Bandyopadhyay
Citation: BMC Public Health 2022 22:104
Content type: Research article
Published on: 15 January 2022

BMC Public Health
http://bmcpublichealth.biomedcentral.com/articles
(Accessed 15 Jan 2022)

Vaccination, politics and COVID-19 impacts
The development of safe and effective COVID-19 vaccines provides a clear path to bring the pandemic to an end. Vaccination rates, however, have been insufficient to prevent disease spread. A critical factor in…
Authors: Don Albrecht
Citation: BMC Public Health 2022 22:96
Content type: Research
Published on: 14 January 2022

BMJ Open
January 2022 – Volume 12 – 1
https://bmjopen.bmj.com/content/12/1

Original research: Attitudes towards vaccines and intention to vaccinate against COVID-19: a cross-sectional analysis—implications for public health communications in Australia (3 January, 2022)
Joanne Enticott, Jaskirath Singh Gill, Simon L. Bacon, Kim L. Lavoie, Daniel S. Epstein, Shrinkhala Dawadi, Helena J Teede, Jacqueline Boyle

BMJ Open
January 2022 – Volume 12 – 1
https://bmjopen.bmj.com/content/12/1

Original research: Factors associated with COVID-19 vaccine receipt at two integrated healthcare systems in New York City: a cross-sectional study of healthcare workers (6 January, 2022)
Kristin Oliver, Anant Raut, Stanley Pierre, Leopolda Silvera, Alexander Boulos, Alyssa Gale, Aaron Baum, Ashley Chory, Nichola J Davis, David D’Souza, Amy Freeman, Crispin Goytia, Andrea Hamilton, Carol Horowitz, Nadia Islam, Jessica Jeavons, Janine Knudsen, Sheng Li, Jenna Lupi, Roxanne Martin, Sheela Maru, Ismail Nabeel, Dina Pimenova, Anya Romanoff, Sonya Rusanov, Nina R Schwalbe, Nita Vangeepuram, Rachel Vreeman, Joseph Masci, Duncan Maru

Bulletin of the World Health Organization
Volume 100(1);  2022 Jan 1
https://www.ncbi.nlm.nih.gov/pmc/issues/397045/

Editorials
Vaccine equity: there is no time to waste
Akhil Bansal
Bull World Health Organ. 2022 Jan 1; 100(1): 2–2A. Published online 2022 Jan 1. doi: 10.2471/BLT.21.287655
PMCID: PMC8722633

Bulletin of the World Health Organization
Volume 100(1);  2022 Jan 1
https://www.ncbi.nlm.nih.gov/pmc/issues/397045/

Research
Data gaps towards health development goals, 47 low- and middle-income countries
Luhua Zhao, Bochen Cao, Elaine Borghi, Somnath Chatterji, Sebastian Garcia-Saiso, Arash Rashidian, Henry Victor Doctor, Marcelo D’Agostino, Humphrey C Karamagi, David Novillo-Ortiz, Mark Landry, Ahmad Reza Hosseinpoor, Abdisalan Noor, Leanne Riley, Adrienne Cox, Jun Gao, Steve Litavecz, Samira Asma
Bull World Health Organ. 2022 Jan 1; 100(1): 40–49. Published online 2021 Nov 4. doi: 10.2471/BLT.21.286254
PMCID: PMC8722627

Bulletin of the World Health Organization
Volume 100(1);  2022 Jan 1
https://www.ncbi.nlm.nih.gov/pmc/issues/397045/

Comparison of national antimicrobial treatment guidelines, African Union
Jessica Craig, Kayli Hiban, Isabel Frost, Geetanjali Kapoor, Yewande Alimi, Jay K Varma
Bull World Health Organ. 2022 Jan 1; 100(1): 50–59. Published online 2021 Nov 26. doi: 10.2471/BLT.21.286689
PMCID: PMC8722630

Bulletin of the World Health Organization
Volume 100(1);  2022 Jan 1
https://www.ncbi.nlm.nih.gov/pmc/issues/397045/

Perspectives
Achieving sustainable health equity
Arachu Castro, Michael Marmot, Juan Garay, Armando de Negri, Paulo Buss, on behalf of the Sustainable Health Equity Movement
Bull World Health Organ. 2022 Jan 1; 100(1): 81–83. Published online 2021 Nov 25. doi: 10.2471/BLT.21.286523
PMCID: PMC8722628

Disaster Medicine and Public Health Preparedness
Volume 15 – Issue 5 – October 2021
https://www.cambridge.org/core/journals/disaster-medicine-and-public-health-preparedness/latest-issue

Policy Analysis
Interdisciplinary Information for Infectious Disease Response: Exercising for Improved Medical/Public Health Communication and Collaboration
Saskia Popescu, Nathan Myers
Published online by Cambridge University Press: 08 September 2020, pp. 546-550

Disaster Medicine and Public Health Preparedness
Volume 15 – Issue 5 – October 2021
https://www.cambridge.org/core/journals/disaster-medicine-and-public-health-preparedness/latest-issue

Original Research
Understanding the Predictors that Contribute to Liberian Health Care Workers Feeling Protected From Ebola While at Work
Kayla Enriquez, Kanagasabai Udhayashankar, Michelle Niescierenko
Published online by Cambridge University Press: 29 May 2020, pp. 589-594

Health Economics, Policy and Law 
Volume 17 – Special Issue 1 – January 2022
https://www.cambridge.org/core/journals/health-economics-policy-and-law/latest-issue

SPECIAL ISSUE: Country Responses to the COVID-19 Pandemic
Articles analyzing country responses in Australia, New Zealand, Canada, U.S., Belgium, Netherlands, Sweden, France, Italy

Humanitarian Exchange Magazine
Number 79, May 2021
https://odihpn.org/magazine/localisation-and-local-humanitarian-action/

Localisation and local humanitarian action
by HPN October 2020
The theme of this edition of Humanitarian Exchange is localisation+ and local humanitarian action. Five years ago this week, donors, United Nations (UN) agencies,  non-governmental organisations (NGOs), the International Committee of the Red Cross (ICRC) and International Federation of Red Cross and Red Crescent Societies (IFRC) committed within the Grand Bargain to increase multi-year investments in the institutional capacities of local and national responders, and to provide at least 25% of humanitarian funding to them as directly as possible. Since then, there is increasing consensus at policy and normative level, underscored by the Covid-19 pandemic, that local leadership should be supported.  Localisation has gone from a fringe conversation among policy-makers and aid agencies in 2016 to a formal priority under the Grand Bargain. Wider global movements on anti-racism and decolonisation have also brought new momentum to critical reflections on where power, knowledge and capacity reside in the humanitarian system. Yet progress has been slow and major gaps remain between the rhetoric around humanitarian partnerships, funding and coordination and practices on the ground.

JAMA
January 11, 2022, Vol 327, No. 2, Pages 105-191
https://jamanetwork.com/journals/jama/currentissue

Research Letter
US State-Level Legal Interventions Related to COVID-19 Vaccine Mandates
Breanna Fernandes; Mark Christopher Navin, PhD; Dorit Rubinstein Reiss, PhD; et al.
free access has active quiz
JAMA. 2022;327(2):178-179. doi:10.1001/jama.2021.22122
This study assesses state-level legal interventions to promote or impede COVID-19 vaccine mandates in the US since the beginning of the pandemic.

JAMA
January 11, 2022, Vol 327, No. 2, Pages 105-191
https://jamanetwork.com/journals/jama/currentissue

Antibody Response and Variant Cross-Neutralization After SARS-CoV-2 Breakthrough Infection
Timothy A. Bates, BSc; Savannah K. McBride, BSc; Bradie Winders, CNA; et al.
free access has active quiz
JAMA. 2022;327(2):179-181. doi:10.1001/jama.2021.22898
This study of fully vaccinated health care workers examines antibody levels and variant cross-neutralization after COVID-19 breakthrough infection.

JAMA
January 11, 2022, Vol 327, No. 2, Pages 105-191
https://jamanetwork.com/journals/jama/currentissue

Viewpoint
One Year of COVID-19 Vaccines A Shot of Hope, a Dose of Reality
Amanda C. Cohn, MD; Barbara E. Mahon, MD, MPH; Rochelle P. Walensky, MD, MPH
free access has multimedia has audio
JAMA. 2022;327(2):119-120. doi:10.1001/jama.2021.23962
This Viewpoint from the CDC reviews how available vaccines have shaped the past year of the COVID-19 pandemic and the challenges that remain.

JAMA Network
COVID-19 Update January 15, 2022

These articles on COVID-19 were published across the JAMA Network in the last week.

Journal of Pharmaceutical Policy and Practice
https://joppp.biomedcentral.com/
[Accessed 15 Jan 2022]

Assessment of COVID-19 vaccines acceptance in the Lebanese population: a national cross-sectional study
Vaccines have become the best weapon for epidemic prevention and control in the absence of standard approved effective therapies. However, skepticism about the vaccine efficacy and safety is constantly reported. To our knowledge, there has been no study assessing COVID-19 vaccine acceptance in Lebanon. The primary objective of this survey is to assess the COVID-19 vaccines’ acceptance and its related determinants in the Lebanese population
Authors: Philippe Hanna, Aline Issa, Ziad Noujeim, Mira Hleyhel and Nadine Saleh
Content type: Research
11 January 2022

Journal of the Royal Society – Interface
January 2022 Volume 19 Issue 186
https://royalsocietypublishing.org/toc/rsif/current

Research articles
Optimal strategies to protect a sub-population at risk due to an established epidemic
Elliott H. Bussell and Nik J. Cunniffe
Published:12 January 2022Article ID:20210718
https://doi.org/10.1098/rsif.2021.0718
Abstract
Epidemics can particularly threaten certain sub-populations. For example, for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the elderly are often preferentially protected. For diseases of plants and animals, certain sub-populations can drive mitigation because they are intrinsically more valuable for ecological, economic, socio-cultural or political reasons. Here, we use optimal control theory to identify strategies to optimally protect a ‘high-value’ sub-population when there is a limited budget and epidemiological uncertainty. We use protection of the Redwood National Park in California in the face of the large ongoing state-wide epidemic of sudden oak death (caused by Phytophthora ramorum) as a case study. We concentrate on whether control should be focused entirely within the National Park itself, or whether treatment of the growing epidemic in the surrounding ‘buffer region’ can instead be more profitable. We find that, depending on rates of infection and the size of the ongoing epidemic, focusing control on the high-value region is often optimal. However, priority should sometimes switch from the buffer region to the high-value region only as the local outbreak grows. We characterize how the timing of any switch depends on epidemiological and logistic parameters, and test robustness to systematic misspecification of these factors due to imperfect prior knowledge.

Journal of Virology
Volume 96 Number 1 January 2022
http://jvi.asm.org/content/current

Articles of Significant Interest in This Issue

Journal of Virology
Volume 96 Number 1 January 2022
http://jvi.asm.org/content/current

SARS-CoV-2 Infection in Human ACE2 Knock-In Mice
Mouse models of SARS-CoV-2 pathogenesis have facilitated the rapid evaluation of antibody and vaccine countermeasures. While the first generation of models developed severe disease after SARS-CoV-2 infection, they relied on ectopic expression of supraphysiological levels of human ACE2 (hACE2). Winkler et al. (e01511-21) evaluated SARS-CoV-2 infection in hACE2 knock-in (KI) mice, which express hACE2 under an endogenous promoter in place of murine ACE2. Infection of hACE2 KI mice with historical or variant SARS-CoV-2 strains resulted in replication within the respiratory tract but did not cause severe pulmonary injury. Thus, the hACE2 KI mouse can serve as a model of mild SARS-CoV-2 lung infection

The Lancet
Jan 15, 2022 Volume 399 Number 10321 p211-334
https://www.thelancet.com/journals/lancet/issue/current

Comment
Mandatory COVID-19 vaccination and human rights
Jeff King, Octávio Luiz Motta Ferraz, Andrew Jones

The Lancet
Jan 15, 2022 Volume 399 Number 10321 p211-334
https://www.thelancet.com/journals/lancet/issue/current

Articles
Final efficacy analysis, interim safety analysis, and immunogenicity of a single dose of recombinant novel coronavirus vaccine (adenovirus type 5 vector) in adults 18 years and older: an international, multicentre, randomised, double-blinded, placebo-controlled phase 3 trial
Scott A Halperin, et al for the CanSino COVID-19 Global Efficacy Study Group
The Ad5-nCoV vaccine is a single-dose adenovirus type 5 (Ad5) vectored vaccine expressing the SARS-CoV-2 spike protein that was well-tolerated and immunogenic in phase 1 and 2 studies. In this study, we report results on the final efficacy and interim safety analyses of the phase 3 trial.

Nature
Volume 601 Issue 7892, 13 January 2022
https://www.nature.com/nature/volumes/601/issues/7892

Editorial | 10 January 2022
COVID is here to stay: countries must decide how to adapt
The Omicron variant has laid bare the need to live with a disease that throws up an ever-changing set of challenges.

From a pandemic perspective, 2022 seemed poised to begin with a hefty dose of déjà vu, with COVID-19 cases on the rise in many countries in the lead-up to the new year. Meanwhile, a new coronavirus variant seemed poised to overwhelm health-care systems amid fears that vaccines — from first inoculations to boosters, depending on the country — could not be rolled out quickly enough to stem the impending tsunami of infections.

The welcome news that surges of the Omicron variant are associated with less severe disease in adults than are preceding variants of SARS-CoV-2 suggests that some of pandemic modellers’ worst-case scenarios will not come to pass. But life has again been disrupted. Widespread absences due to coronavirus infections have left hospitals in many countries understaffed, forced schoolchildren to return to remote learning, and limited global mobility. And even if a relatively small percentage of those infected require hospitalization, sky-high infection rates across large populations mean that many people will still face life-threatening disease and long-term disability. This is particularly true for the unvaccinated — a group that includes a large proportion of the world’s population, especially children.

For those who had hoped that 2021 would be the year that put the pandemic in the past tense, it was a harsh reminder that it is still very much present. Rather than laying plans to return to the ‘normal’ life we knew before the pandemic, 2022 is the year the world must come to terms with the fact that SARS-CoV-2 is here to stay.

Countries must decide how they will live with COVID-19 — and living with COVID-19 does not mean ignoring it. Each region must work out how to balance the deaths, disability and disruption caused by the virus with the financial and societal costs of measures used to try to control the virus, such as mask mandates and business closures. This balance will vary from one place to another, and with time, as more therapies and vaccines become available — and as new variants emerge.

The emergence of the Omicron variant last November highlighted the ongoing challenges of life with SARS-CoV-2. Some countries were already facing surges in the highly transmissible Delta variant, but vaccines and prior infection conferred relatively high levels of protection against Delta, particularly against severe disease. Many researchers — and a fair few politicians — hoped that future waves would be less disruptive, thanks to the build-up of immunity in populations that would keep viral circulation in check and protect most people from the severe manifestations of disease that drain health-care resources.

It was expected that mutations in the viral genome would slowly chip away at this immunity, particularly its ability to stop viral transmission. But Omicron dealt a swifter and more serious blow to immunity than predicted. It is now clear that SARS-CoV-2 reinfections are more common, and that some of the most widely used COVID-19 vaccines have faltered in the face of the variant. Existing vaccines, developed against an earlier variant, now require a booster to provide substantial levels of protection against infection.

But the news has not all been grim. Vaccines, particularly when boosted, still seem to provide substantial protection against severe disease and death. Early data from animal studies suggest that Omicron might generate a different pathology compared with previous variants, causing greater infection of the upper respiratory tract and less infection in the lungs. Data from several countries suggest that the variant is associated with less severe disease, although whether this is due to the variant itself or widespread pre-existing immunity requires further study.

Countries have charted a variety of courses through the latest surge. Many with the resources have accelerated the distribution of vaccine boosters, but many others do not have this luxury. Some countries have reinstituted lockdowns, whereas others are holding back, waiting to see the extent to which climbing infection rates affect hospitals.

With infection rates soaring around the globe and many countries still unable to access adequate vaccine supplies, more SARS-CoV-2 variants of concern will continue to emerge. And, as Omicron has illustrated, the ability to predict what course those variants will take becomes more difficult as the complexities of viral evolution and pre-existing immunity complicate the models that have previously been used to anticipate the course of the pandemic. Now modellers need to factor in the effects of vaccines, previous infections, waning immunity over time, booster shots and viral variants — and, as the year progresses, they will also have to consider the impact of emerging antiviral treatments.

But what is clear is that the hope that vaccines and prior infection could generate herd immunity to COVID-19 — an unlikely possibility from the start — has all but disappeared. It is widely thought that SARS-CoV-2 will become endemic rather than extinct, with vaccines providing protection from severe disease and death, but not eradicating the virus.

As Omicron and other variants have shown, this only adds to the urgency with which vaccines must be distributed to countries that currently lack supplies. Efforts are under way to bolster vaccine production in countries such as South Africa, which have not historically been centres for vaccine manufacturing. These and other efforts to boost global access to vaccines remain in the best interests of all countries: devastating variants are particularly likely to emerge and seed blazing outbreaks in regions with low vaccination rates, and their spread will be further exacerbated where levels of testing and genomic surveillance are also low.

Fortunately, 2022 is poised to add to our defences against the pandemic. New vaccines — such as protein-based vaccines, which might cost less and have less-stringent storage requirements than mRNA vaccines currently do — will become more widely available. In December, the World Health Organization approved the long-awaited protein vaccine made by Novavax in Gaithersburg, Maryland, for emergency use. Ongoing clinical trials will establish whether upcoming vaccine candidates that target specific coronavirus variants, or that can be inhaled or taken orally rather than injected, will also be useful. Several nasal candidates are in clinical testing, including one from CanSino in Tianjin, China, and another developed by AstraZeneca in Cambridge, UK.

Meanwhile, new antiviral drugs, formulated in tablets that can be easily administered early in the course of infection to reduce the chance of serious disease and death, offer another approach against COVID-19. In the past few months, some countries have authorized the use of two such drugs: molnupiravir, made by Merck in Kenilworth, New Jersey, and Ridgeback Biotherapeutics in Miami, Florida; and Paxlovid, made by Pfizer, based in New York. Data from pivotal clinical trials of other candidates are expected in the coming year.

All of these will expand the world’s capacity to manage SARS-CoV-2 outbreaks. They are cause for hope and optimism, but with a hefty dose of realism: the virus will continue to circulate and change, and governments must continue to rely on the guidance and advice of scientists. We will not always be able to predict the virus’s path, and we must be ready to adapt with it.

Comment
Unblock research bottlenecks with non-profit start-ups
‘Focused research organizations’ can take on mid-scale projects that don’t get tackled by academia, venture capitalists or government labs.
Adam Marblestone, Anastasia Gamick, Samuel G. Rodriques
It takes more than a great idea to accomplish a great project. Our research and experience have convinced us that many worthy projects wither or are never launched because neither academic laboratories, start-up firms nor government facilities can support them.
This applies particularly to projects that would produce public goods, such as data sets or tools, that could make research faster and easier. Few research-enabling projects will be commercially viable enough to attract venture capital. Nor is academia a suitable incubator. Academics can rarely muster the time, focus and workforce coordination needed to turn a proof-of-principle technology into a robust, scalable technique or to transform a research project into a platform. These engineering improvements do not fulfil teaching requirements or provide the papers or pizzazz that both senior academics and their trainees need to propel their careers.
A type of non-profit start-up could be a better way to support projects that enable research. These would have full-time scientists, engineers and executives, and total funding of about US$20 million to $100 million that would last around 5 years — longer than most grants or venture-capital funding rounds allow. And they would be set up to pursue predefined milestones, such as improving the resolution of a measurement system by tenfold, or gathering a pre-specified amount of data. We call them focused research organizations (FROs)…

New England Journal of Medicine
January 13, 2022 Vol. 386 No. 2
http://www.nejm.org/toc/nejm/medical-journal

Perspective
Adolescents, Parents, and Covid-19 Vaccination — Who Should Decide? S. McGrew and H.A. Taylor
Covid-19 vaccination for adolescents (for these purposes, children 12 to 17 years of age) is
important, both for their own mental and physical health and for public health…

New England Journal of Medicine
January 13, 2022 Vol. 386 No. 2
http://www.nejm.org/toc/nejm/medical-journal

Original Articles
Comparative Effectiveness of BNT162b2 and mRNA-1273 Vaccines in U.S. Veterans B.A. Dickerman and Others

New England Journal of Medicine
January 13, 2022 Vol. 386 No. 2
http://www.nejm.org/toc/nejm/medical-journal

Covid-19 Vaccine Effectiveness in New York State E.S. Rosenberg and Others

PLoS Medicine
http://www.plosmedicine.org/
(Accessed 15 Jan 2022)

Political rationale, aims, and outcomes of health-related high-level meetings and special sessions at the UN General Assembly: A policy research observational study
Paolo Rodi, Werner Obermeyer, Ariel Pablos-Mendez, Andrea Gori, Mario C. Raviglione
Research Article | published 13 Jan 2022 PLOS Medicine
https://doi.org/10.1371/journal.pmed.1003873
Recognising the substantial political weight of the United Nations General Assembly (UNGA), a UN General Assembly special session (UNGASS) and high-level meetings (HLMs) have been pursued and held for 5 health-related topics thus far. They have focused on human immunodeficiency virus/acquired immune deficiency syndrome (HIV/AIDS, 2001), non-communicable diseases (NCDs, 2011), antimicrobial resistance (AMR, 2016), tuberculosis (TB, 2018), and universal health coverage (UHC, 2019). This observational study presents a comprehensive analysis of the political and policy background that prompted the events, as well as an assessment of aims, approaches, and ultimate outcomes.

PLoS Medicine
http://www.plosmedicine.org/
(Accessed 15 Jan 2022)

Safety and immunogenicity of 2-dose heterologous Ad26.ZEBOV, MVA-BN-Filo Ebola vaccination in children and adolescents in Africa: A randomised, placebo-controlled, multicentre Phase II clinical trial
Zacchaeus Anywaine, Houreratou Barry, Omu Anzala, Gaudensia Mutua, Sodiomon B. Sirima, Serge Eholie, Hannah Kibuuka, Christine Bétard, Laura Richert, Christine Lacabaratz, M. Juliana McElrath, Stephen C. De Rosa, Kristen W. Cohen, Georgi Shukarev, Michael Katwere, Cynthia Robinson, Auguste Gaddah, Dirk Heerwegh, Viki Bockstal, Kerstin Luhn, Maarten Leyssen, Rodolphe Thiébaut, Macaya Douoguih, on behalf of the EBL2002 Study group
Research Article | published 11 Jan 2022 PLOS Medicine
https://doi.org/10.1371/journal.pmed.1003865

PLoS Neglected Tropical Diseases
http://www.plosntds.org/
(Accessed 15 Jan 2022)

Effects of vaccination and non-pharmaceutical interventions and their lag times on the COVID-19 pandemic: Comparison of eight countries
Hao Li, Luqi Wang, Mengxi Zhang, Yihan Lu, Weibing Wang
Research Article | published 13 Jan 2022 PLOS Neglected Tropical Diseases
https://doi.org/10.1371/journal.pntd.0010101
Abstract
Many countries implemented measures to control the COVID-19 pandemic, but the effects of these measures have varied greatly. We evaluated the effects of different policies, the prevalence of dominant variants (e.g., Delta), and vaccination on the characteristics of the COVID-19 pandemic in eight countries. We quantified the lag times of different non-pharmaceutical interventions (NPIs) and vaccination using a distributed lag non-linear model (DLNM). We also tested whether these lag times were reasonable by analyzing changes in daily cases and the effective reproductive number (Rt)over time. Our results indicated that the response to vaccination in countries with continuous vaccination programs lagged by at least 40 days, and the lag time for a response to NPIs was at least 14 days. A rebound was most likely to occur during the 40 days after the first vaccine dose. We also found that the combination of school closure, workplace closure, restrictions on mass gatherings, and stay-at-home requirements were successful in containing the pandemic. Our results thus demonstrated that vaccination was effective, although some regions were adversely affected by new variants and low vaccination coverage. Importantly, relaxation of NPIs soon after implementation of a vaccination program may lead to a rebound.

PLoS One
http://www.plosone.org/
[Accessed 15 Jan 2022]

Research Article
Impact of Coronavirus Infectious Disease (COVID-19) pandemic on willingness of immunization—A community-based questionnaire study
Pei-Yun Chen, Pei-Ni Chuang, Chien-Hsieh Chiang, Hao-Hsiang Chang, Chia-Wen Lu, Kuo-Chin Huang
Research Article | published 14 Jan 2022 PLOS ONE
https://doi.org/10.1371/journal.pone.0262660

PLoS One
http://www.plosone.org/
[Accessed 15 Jan 2022]

COVID-19 vaccine acceptance among Bangladeshi adults: Understanding predictors of vaccine intention to inform vaccine policy
Clarice Lee, Taylor A. Holroyd, Rachel Gur-Arie, Molly Sauer, Eleonor Zavala, Alicia M. Paul, Dominick Shattuck, Ruth A. Karron, Rupali J. Limaye
Research Article | published 13 Jan 2022 PLOS ONE
https://doi.org/10.1371/journal.pone.0261929

PLoS One
http://www.plosone.org/
[Accessed 15 Jan 2022]

Twitter and Facebook posts about COVID-19 are less likely to spread misinformation compared to other health topics
David A. Broniatowski, Daniel Kerchner, Fouzia Farooq, Xiaolei Huang, Amelia M. Jamison, Mark Dredze, Sandra Crouse Quinn, John W. Ayers
Research Article | published 12 Jan 2022 PLOS ONE
https://doi.org/10.1371/journal.pone.0261768

PLoS One
http://www.plosone.org/
[Accessed 15 Jan 2022]

Conspiracy beliefs and vaccination intent for COVID-19 in an infodemic
Ali Ghaddar, Sanaa Khandaqji, Zeinab Awad, Rawad Kansoun
Research Article | published 12 Jan 2022 PLOS ONE
https://doi.org/10.1371/journal.pone.0261559

PLoS One
http://www.plosone.org/
[Accessed 15 Jan 2022]

A systematic review of methodological approaches for evaluating real-world effectiveness of COVID-19 vaccines: Advising resource-constrained settings
Yot Teerawattananon, Thunyarat Anothaisintawee, Chatkamol Pheerapanyawaranun, Siobhan Botwright, Katika Akksilp, Natchalaikorn Sirichumroonwit, Nuttakarn Budtarad, Wanrudee Isaranuwatchai
Research Article | published 11 Jan 2022 PLOS ONE
https://doi.org/10.1371/journal.pone.0261930

PNAS – Proceedings of the National Academy of Sciences of the United States
December 21, 2021; vol. 118 no. 51
https://www.pnas.org/content/118/51

Beyond Cases and Deaths: The Benefits of Auxiliary Data Streams In Tracking the COVID-19 Pandemic
Epidemic tracking and forecasting: Lessons learned from a tumultuous year
From the Cover
Roni Rosenfeld and Ryan J. Tibshirani
PNAS December 21, 2021 118 (51) e2111456118; https://doi.org/10.1073/pnas.2111456118

PNAS – Proceedings of the National Academy of Sciences of the United States
December 21, 2021; vol. 118 no. 51
https://www.pnas.org/content/118/51

An open repository of real-time COVID-19 indicators
Alex Reinhart, Logan Brooks, Maria Jahja, Aaron Rumack, Jingjing Tang, Sumit Agrawal, Wael Al Saeed, Taylor Arnold, Amartya Basu, Jacob Bien, Ángel A. Cabrera, Andrew Chin, Eu Jing Chua, Brian Clark, Sarah Colquhoun, Nat DeFries, David C. Farrow, Jodi Forlizzi, Jed Grabman, Samuel Gratzl, Alden Green, George Haff, Robin Han, Kate Harwood, Addison J. Hu, Raphael Hyde, Sangwon Hyun, Ananya Joshi, Jimi Kim, Andrew Kuznetsov, Wichada La Motte-Kerr, Yeon Jin Lee, Kenneth Lee, Zachary C. Lipton, Michael X. Liu, Lester Mackey, Kathryn Mazaitis, Daniel J. McDonald, Phillip McGuinness, Balasubramanian Narasimhan, Michael P. O’Brien, Natalia L. Oliveira, Pratik Patil, Adam Perer, Collin A. Politsch, Samyak Rajanala, Dawn Rucker, Chris Scott, Nigam H. Shah, Vishnu Shankar, James Sharpnack, Dmitry Shemetov, Noah Simon, Benjamin Y. Smith, Vishakha Srivastava, Shuyi Tan, Robert Tibshirani, Elena Tuzhilina, Ana Karina Van Nortwick, Valérie Ventura, Larry Wasserman, Benjamin Weaver, Jeremy C. Weiss, Spencer Whitman, Kristin Williams, Roni Rosenfeld, and Ryan J. Tibshirani
PNAS December 21, 2021 118 (51) e2111452118; https://doi.org/10.1073/pnas.2111452118
Open Access

PNAS – Proceedings of the National Academy of Sciences of the United States
December 21, 2021; vol. 118 no. 51
https://www.pnas.org/content/118/51

Can auxiliary indicators improve COVID-19 forecasting and hotspot prediction?
Daniel J. McDonald, Jacob Bien, Alden Green, Addison J. Hu, Nat DeFries, Sangwon Hyun, Natalia L. Oliveira, James Sharpnack, Jingjing Tang, Robert Tibshirani, Valérie Ventura, Larry Wasserman, and Ryan J. Tibshirani
PNAS December 21, 2021 118 (51) e2111453118; https://doi.org/10.1073/pnas.2111453118
Open Access

PNAS – Proceedings of the National Academy of Sciences of the United States
December 21, 2021; vol. 118 no. 51
https://www.pnas.org/content/118/51

The US COVID-19 Trends and Impact Survey: Continuous real-time measurement of COVID-19 symptoms, risks, protective behaviors, testing, and vaccination
Joshua A. Salomon, Alex Reinhart, Alyssa Bilinski, Eu Jing Chua, Wichada La Motte-Kerr, Minttu M. Rönn, Marissa B. Reitsma, Katherine A. Morris, Sarah LaRocca, Tamer H. Farag, Frauke Kreuter, Roni Rosenfeld, and Ryan J. Tibshirani
PNAS December 21, 2021 118 (51) e2111454118; https://doi.org/10.1073/pnas.2111454118
Open Access

PNAS – Proceedings of the National Academy of Sciences of the United States
December 21, 2021; vol. 118 no. 51
https://www.pnas.org/content/118/51

Global monitoring of the impact of the COVID-19 pandemic through online surveys sampled from the Facebook user base
Christina M. Astley, Gaurav Tuli, Kimberly A. Mc Cord, Emily L. Cohn, Benjamin Rader, Tanner J. Varrelman, Samantha L. Chiu, Xiaoyi Deng, Kathleen Stewart, Tamer H. Farag, Kristina M. Barkume, Sarah LaRocca, Katherine A. Morris, Frauke Kreuter, and John S. Brownstein
PNAS December 21, 2021 118 (51) e2111455118; https://doi.org/10.1073/pnas.2111455118